Heather M Gibson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8451060/publications.pdf

Version: 2024-02-01

759233 713466 27 692 12 21 citations h-index g-index papers 28 28 28 1235 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. Genes and Immunity, 2014, 15, 25-32.	4.1	99
2	Induction of the <i>CTLA-4</i> Gene in Human Lymphocytes Is Dependent on NFAT Binding the Proximal Promoter. Journal of Immunology, 2007, 179, 3831-3840.	0.8	94
3	Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides. Clinical Cancer Research, 2008, 14, 646-653.	7.0	82
4	IFN \hat{I}^3 PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy. Cancer Research, 2018, 78, 5706-5717.	0.9	79
5	Increased Expression of CTLA-4 in Malignant T Cells from Patients with Mycosis Fungoides – Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 2006, 126, 212-219.	0.7	72
6	In vivo Imaging Technologies to Monitor the Immune System. Frontiers in Immunology, 2020, 11, 1067.	4.8	45
7	Impaired Proteasome Function Activates GATA3 in T Cells and Upregulates CTLA-4: Relevance for Sézary Syndrome. Journal of Investigative Dermatology, 2013, 133, 249-257.	0.7	41
8	Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome. Journal of Investigative Dermatology, 2015, 135, 2084-2092.	0.7	32
9	Layer-by-Layer Films with Bioreducible and Nonbioreducible Polycations for Sequential DNA Release. Biomacromolecules, 2014, 15, 3965-3975.	5.4	28
10	Cryotherapy with Concurrent CpG Oligonucleotide Treatment Controls Local Tumor Recurrence and Modulates HER2/neu Immunity. Cancer Research, 2014, 74, 5409-5420.	0.9	20
11	Induction of proapoptotic antibodies to tripleâ€negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. International Journal of Cancer, 2012, 131, 2562-2572.	5.1	17
12	Evolution of animal models in cancer vaccine development. Vaccine, 2015, 33, 7401-7407.	3.8	14
13	Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination. Cancer Immunology Research, 2015, 3, 777-786.	3.4	13
14	Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors. Oncolmmunology, 2015, 4, e984523.	4.6	10
15	RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA. Oncogene, 2021, 40, 6430-6442.	5.9	10
16	A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors. Oncolmmunology, 2022, 11, 2064958.	4.6	10
17	Diversity Outbred Mice Reveal the Quantitative Trait Locus and Regulatory Cells of HER2 Immunity. Journal of Immunology, 2020, 205, 1554-1563.	0.8	8
18	<i>In situ</i> iinmunization via non-surgical ablation to prevent local and distant tumor recurrence. Oncolmmunology, 2015, 4, e989762.	4.6	6

#	Article	IF	Citations
19	Removal of Fc Glycans from [⁸⁹ Zr]Zr-DFO-Anti-CD8 Prevents Peripheral Depletion of CD8 ⁺ T Cells. Molecular Pharmaceutics, 2020, 17, 2099-2108.	4.6	5
20	Evaluation of an ImmunoPET Tracer for IL-12 in a Preclinical Model of Inflammatory Immune Responses. Frontiers in Immunology, 2022, 13 , .	4.8	5
21	An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice. Cancer Immunology, Immunotherapy, 2019, 68, 1143-1155.	4.2	2
22	Abstract 2858: A novel mouse model for cutaneous T-cell lymphoma reveals a role for IL-15 and activity of a new oral HDAC inhibitor. , $2011, \ldots$		0
23	Abstract 3857: Targeting HDAC1 in a novel model of cutaneous T-cell lymphoma , 2013, , .		O
24	Abstract 470: Electrovaccination of domestic cats with a hybrid heterologous Her2 DNA vaccine overcomes immune tolerance to self Her2 , 2013, , .		0
25	The importance of examining an active immune system during immunotherapy. Oncotarget, 2019, 10, 559-560.	1.8	O
26	Abstract P060: Identification of host-intrinsic resistance mechanisms to immune checkpoint inhibitors (ICI) in Diversity Outbred mice. , 2022, , .		0
27	Abstract P055: Evaluation of an immuno PET tracer for IL-12 in a preclinical model of inflammatory immune responses. , 2022, , .		O